About Diasome
Diasome is a company based in Cleveland (United States) founded in 2005 by W Blair Geho. Diasome has raised $72.63 million across 14 funding rounds from investors including Lilly, Medicxi and Black Beret Life Sciences. Diasome offers products and services including HDV Platform, OPTI-2 Clinical Trial, Oral HDV-GLP-1, and Injectable HDV-Rapid Acting Insulin. Diasome operates in a competitive market with competitors including Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics, Neurocrine and Cellino, among others.
- Headquarter Cleveland, United States
- Founders W Blair Geho
- SectorsHealthcare
- Website diasome.com
- Total Equity Funding$72.63M (USD)
in 14 rounds
- Latest Funding Round$3.09M (USD), Series C
Jul 2024
- InvestorsLilly
& 4 more
Products & Services of Diasome
Diasome offers a comprehensive portfolio of products and services, including HDV Platform, OPTI-2 Clinical Trial, Oral HDV-GLP-1, and Injectable HDV-Rapid Acting Insulin.
Delivers targeted therapies to hepatocyte cells for metabolic disease treatment.
Investigates new insulin therapy for Type 1 Diabetes patients.
Targets GLP-1 delivery for obesity and diabetes management.
Provides fast insulin action for blood sugar control.
Funding Insights of Diasome
Diasome has successfully raised a total of $72.63M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $3.09 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $72.63M
- Total Rounds 14
- Last Round Series C — $3.09M
- First Round $350,000
(Sep 2007)
- Investors Count 5
Latest 10 of 14 funding rounds of Diasome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $3.09M | Series C | – | – | – |
| Dec 2023 | – | Series C | – | – | |
| Jun 2023 | $9M | Series B | – | – | – |
| Dec 2020 | $1.5M | Series B | – | – | – |
| Apr 2020 | $2.89M | Series B | – | – | – |
| Oct 2018 | $12.08M | Debt – Conventional | – | – | – |
| Jul 2017 | $30M | Series B | – | Medicxi | |
| Jan 2017 | $4.35M | Debt – Conventional | – | – | – |
| Dec 2016 | $4.35M | Debt – Conventional | – | – | – |
| Apr 2009 | $12.9M | Series B | – | – | – |
5 investors in total: 5 institutional.
Investors in Diasome
Diasome has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Medicxi and Black Beret Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage life science focused VC firm investing in geographies such as Europe and the US | – | medicxi.com | London, United Kingdom | |
- | – | bbls.net | - | |
Companies developing T1D products are funded through venture philanthropy. | – | t1dfund.org | Boston, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
Provides financial planning, investment management, and retirement services for clients. | 2005 | mcdonald-partners.com | Cleveland, United States |
Investor details for Diasome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Diasome
12 people are tracked at Diasome (5 in leadership, 7 in board & advisors).
| Name | Role | Group |
|---|---|---|
W Blair Geho | Founder & Director | Leadership |
Marc Penn | Chief Medical Officer | Leadership |
Christine Smith | Chief Manufacturing Officer | Leadership |
Robert Geho | Co-Founder & CEO | Leadership |
Douglas Muchmore | Chief Technology Officer | Leadership |
Frank McCaney | Chairman | Board & advisors |
Martin Lafontaine | Advisor | Board & advisors |
Bruce Bode | Advisor | Board & advisors |
Eric Edidin | Board Observer | Board & advisors |
Jeremy Pettus | Advisor | Board & advisors |
Peter A. Tollman | Board Member | Board & advisors |
Thomas McDonald | Board Member | Board & advisors |
Complete people profiles for Diasome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Diasome
3 dated milestones of Diasome across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Diasome is founded.
- Funding First funding round of $350K.
- Funding Latest funding round, Series C, of $3.1M.
Competitors of Diasome
Diasome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics, Neurocrine and Cellino, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| adocia.com | 2005 | Lyon, France | $26M | – | Therapeutics for diabetes and obesity treatment are developed. | |
| pendulumlife.com | 2012 | San Francisco, United States | $109.5M | 55 | Pendulum is focused on developing advanced probiotic solutions. | |
| rezolutebio.com | 2012 | Denver, United States | – | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| zucara.ca | 2015 | Vancouver, Canada | $50.82M | 12 | Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes |
Detailed competitors of Diasome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Diasome
The website of Diasome (diasome.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 7.5% vs previous month
Latest news on Diasome
Complete news archive for Diasome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Diasome
10 companies that operate in the same segment as Diasome (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 245.2 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Diasome
Diasome was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Diasome is headquartered in Cleveland, United States. It is registered at Cleveland, Ohio, United States.
Diasome is a funded company, having raised a total of $72.63M across 14 funding rounds to date. The company's 1st funding round was a Series B of $12.9M, raised on Sep 2007.
Diasome was founded in 2005 in Cleveland, United States, within the biotechnology sector. Therapies for diabetes and other metabolic conditions are developed, with a focus on the Hepatocyte Directed Vesicles (HDV) system. This liver-targeted delivery method for insulin is designed to minimize hypoglycemia risks among diabetic patients. Operations center on advancing these targeted treatments for improved metabolic management.
Diasome's top competitors include Crinetics, Neurocrine and Sana Biotechnology.
Diasome offers HDV Platform, OPTI-2 Clinical Trial, Oral HDV-GLP-1, and Injectable HDV-Rapid Acting Insulin.
Diasome has 5 investors. Key investors include Lilly, Medicxi, Black Beret Life Sciences, T1D Fund, and McDonald Partners.